FDA announces scientific conference on CBD use and response differences between sexes and genders
The U.S. Food and Drug Administration’s Office of Women’s Health has announced that it will be hosting a public meeting discussing the potential sex (biological) and gender (psychosocial) differences in the consumption of and response to cannabidiol (CBD) and other cannabinoids.
Photo © AdobeStock.com/Elroi
The U.S. Food and Drug Administration’s Office of Women’s Health has announced that it will be hosting a public meeting discussing the potential sex (biological) and gender (psychosocial) differences in the consumption of and response to cannabidiol (CBD) and other cannabinoids. The multidisciplinary scientific conference, titled “CBD and Other Cannabinoids: Sex and Gender Differences in Use and Responses,” is designed for the benefit of researchers, educators, clinicians, and patients, alike.
“Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of CBD and other cannabinoids, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation,” states FDA is its announcement.
The conference, which is an outcome of FDA’s ongoing information and data gathering efforts through public docket, will take place on November 19, 2020 from 9 am to 4 pm.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
